Last reviewed · How we verify

NCT06639529

Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease

Completed NA Last updated 15 October 2024
What this trial tests

NA trial testing Tests of the expression of CXCL3 in various tissues in Diabetic Kidney Disease (DKD) in 120 participants. Completed in 30 July 2024.

Timeline
10 June 2024
Primary endpoint
30 July 2024
30 July 2024

Quick facts

Lead sponsorThe First Hospital of Jilin University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment120
Start date10 June 2024
Primary completion30 July 2024
Estimated completion30 July 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Hospital of Jilin University

Who can join

Adults 18 to 80, any sex, with Diabetic Kidney Disease (DKD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to learn about CXCL3 as a biomarker for type 2 diabetic kidney disease (DKD) in adults between age of 18-80. The main question it aims to answer is: * Is CXCL3 elevated in the serum or urine of type 2 adult DKD patients compared to normal control or diabetes mellitus without kidney involvement? * Is CXCL3 elevated in the mRNA of PBMC of type 2 adult DKD patients compared to normal control or diabetes mellitus without kidney involvement? * Is CXCL3 elevated in the kidney tissue of type 2 adult DKD patients compared to normal control or other glomerulonephritis? Participants have already been diagnosed as DKD by renal biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetic Kidney Disease (DKD)

Currently open trials in the same condition.

Other The First Hospital of Jilin University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing